Cargando…
Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372992/ https://www.ncbi.nlm.nih.gov/pubmed/35199579 http://dx.doi.org/10.18553/jmcp.2022.28.3.376 |
| _version_ | 1785078469759074304 |
|---|---|
| author | Taddei-Allen, Patty |
| author_facet | Taddei-Allen, Patty |
| author_sort | Taddei-Allen, Patty |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10372992 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103729922023-07-31 Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy Taddei-Allen, Patty J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2022-03 /pmc/articles/PMC10372992/ /pubmed/35199579 http://dx.doi.org/10.18553/jmcp.2022.28.3.376 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Perspectives on Value Taddei-Allen, Patty Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy |
| title | Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy |
| title_full | Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy |
| title_fullStr | Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy |
| title_full_unstemmed | Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy |
| title_short | Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy |
| title_sort | considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy |
| topic | Perspectives on Value |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372992/ https://www.ncbi.nlm.nih.gov/pubmed/35199579 http://dx.doi.org/10.18553/jmcp.2022.28.3.376 |
| work_keys_str_mv | AT taddeiallenpatty considerationsformanagedcarepharmacyinevaluatingmavacamtenanovelagentforobstructivehypertrophiccardiomyopathy |